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Abstract
Patients with polycythemia vera (PV) have a substantial risk of thrombotic events (TEs). In the present retro-
spective analysis using Veterans Health Administration claims data, 25% of 1565 patients experienced a TE
during follow-up. We observed a positive, significant association between white blood cell (WBC)
counts ‡ 8.5 3 109/L and TE occurrence (reference, WBC count < 7.0 3 109/L), supporting continued inclusion
of WBC count control in disease management.
Background: Patients with polycythemia vera (PV) have a substantial risk of thrombotic events (TEs). The objective of
the present analysis was to describe the association between white blood cell (WBC) levels and occurrence of TEs
among patients with PV from a large real-world population. Patients and Methods: The present retrospective analysis
using Veterans Health Administration claims data (October 1, 2005, to September 30, 2012) evaluated adult patients
assigned to 4 WBC count categories (WBC count < 7.0, 7.0-8.4, 8.5 to < 11.0, and  11.0  109/L) to compare the
risk of TEs (reference, WBC count, < 7.0  109/L group). Analysis was performed using a Cox proportional hazards
model, considering WBC status as a time-dependent covariate. Results: Of the 1565 patients with PV included in the
present analysis, the WBC count was < 7.0  109/L for 428 (27.3%), 7.0 to 8.4  109/L for 375 (24.0%), 8.5 to <
11.0  109/L for 284 (18.1%), and  11.0  109/L for 478 (30.5%). Of the 1565 patients, 390 (24.9%) had experienced
a TE during the study period. The mean follow-up ranged from 3.6 to 4.5 years. Compared with the reference group
(WBC count < 7.0 109/L), the hazard ratio for TEs was 1.10 (95% confidence interval [CI], 0.82-1.48; P ¼ .5395), 1.47
(95% CI, 1.10-1.96; P ¼ .0097), and 1.87 (95% CI, 1.44-2.43; P < .0001) for patients with a WBC count of 7.0 to 8.4,
8.5 to < 11.0, and  11.0 109/L, respectively. Conclusion: A positive, significant association between an increased
WBC count of  8.5 109/L and the occurrence of TEs was observed in patients with PV. The potential thrombogenic
role of WBCs in patients with PV supports the continued inclusion of WBC count control in disease management and
evaluation of the response to therapy.
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The primary treatment goals for patients with polycythemia vera
(PV) have focused on the prevention or management of thrombotic
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VHA PV WBC and TE Analysisconfirmed in a post hoc subanalysis of the prospective, randomized
CYTO-PV (cytoreductive therapy in polycythemia vera) study,
which demonstrated a significant correlation between an elevated
white blood cell (WBC) count ( 11 109/L) and time-dependent
risk of major thrombosis (hazard ratio, 3.9; 95% confidence interval
[CI], 1.24-12.3).4
The objective of the present analysis was to describe the associ-
ation between the WBC counts and the occurrence of TEs among
patients with PV from a large real-world population using data from
the US Veterans Health Administration (VHA). The VHA is the
largest integrated healthcare system in the United States, with > 9
million enrollees and longitudinal tracking of patient care.
Patients and Methods
Study Design
This was a retrospective, observational study of longitudinal data
from the VHA claims database collected from October 1, 2005, to
September 30, 2012 (Figure 1). The data set included de-identified
patient-level data from 21 Veterans Integrated Service Networks
linking inpatient, outpatient, pharmacy, laboratory, enrollment, and
vital sign databases. The present analysis complied with the Health
Insurance Portability and Accountability Act of 1996 and its
implementing regulations (Health Insurance Portability and
Accountability Act Privacy and Security Rules) for the use of de-
identified patient data.
Patients
Adult patients were included in the analysis if they had  2
claims for PV (International Classification of Diseases, ClinicalFigure 1 Study Design. *Period ‡ 12 Months. yPatients Were Follow










Index date = date of PV diag
Abbreviation: PV ¼ polycythemia vera.
nical Lymphoma, Myeloma & Leukemia Month 2019Modification [ICD-9-CM], code 238.4)  30 days apart during the
identification period (October 1, 2006, through September 30,
2007). Additional inclusion criteria were patient age  18 years at
the first PV diagnosis claim (index date), continuous health plan
enrollment with medical and pharmacy benefits for  12 months
before the index date, and  3 WBC counts annually on average
during the follow-up period. For patients with a TE,  1 WBC
count before the TE was required. If no WBC count had been
reported before the first TE, the patient was excluded from the
analysis. Patients were also excluded from the main analysis if they
had experienced a TE before the index date. The follow-up period
began on the index date (date of the first PV diagnosis claim) and
ended at death, disenrollment, or the end of the study period,
whichever occurred first.
Variables
Patients were assigned to 1 of the following groups according to
the last WBC measurement before the first TE or the end of the
follow-up period: WBC count < 7.0, 7.0 to 8.4, 8.5 to < 11.0,
and  11.0 109/L. TEs were determined using ICD-9-CM
codes and included ischemic stroke, acute myocardial infarction,
deep vein thrombosis, pulmonary embolism, transient ischemic
attack, peripheral arterial thrombosis, and superficial
thrombophlebitis.
Statistical Analysis
All demographic and baseline clinical characteristics were
compared among the patients stratified by the last WBC measure-









Shreekant Parasuraman et alhazards model, with the WBC count considered as a time-
dependent covariate and < 7.0 109/L as the reference group.
This analysis was conducted using the linear interpolation approach
between 2 WBC records to determine the WBC count at the time
of a TE. Using this determined WBC count, the patients were
designated to 1 of 4 WBC categories (separate from group alloca-
tions per primary analyses). The categorical variables were then
applied for the time-dependent covariate approach. Binary variables
were created for the patients within each of the 4 WBC categories
(WBC count, 0-7.0, 7.0-8.4, 8.5 to < 11.0, and  11.0  109/L),
with the WBC count < 7.0  109/L category considered the
reference. A second analysis included a univariate Cox proportional
hazards model using the last WBC count before a TE. The purpose
of this second analysis was to approximate the methods used in the
CYTO-PV study and, therefore, did not consider the WBC count
as a time-dependent covariate. A sensitivity analysis was performed,
repeating the analysis with all patients, including both those with
and without a history of thrombosis. The time from the index date
to the first TE was censored at death, disenrollment, or the end of
the study period.Figure 2 Flow Chart Showing Patient Selection
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N=394
≥18 years old on th
n=392
Had continuous health plan enrollment
≥12 months pre-index un
n=388
≥3 Hct values per year durin
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Abbreviations: Hct ¼ hematocrit; PV ¼ polycythemia vera; TE ¼ thrombotic event; WBC ¼ white bResults
Patient Demographics and Baseline Clinical
Characteristics
The analysis included a total of 1565 US veterans with PV and no
history of thrombosis. The WBC count was < 7.0 109/L for 428
(27.3%), 7.0 to 8.4109/L for 375 (24.0%), 8.5 to< 11.0109/L
for 284 (18.1%), and 11.0109/L for 478 (30.5%; Figure 2). The
patient demographics were similar across the 4 groups, with most
patients aged 60 years (66.8%), male (98.5%), and white (65.3%;
Table 1). The mean Charlson comorbidity index and chronic disease
scores were similar across the 4 groups and ranged from 1.11 to 1.45
and 6.15 to 6.76, respectively. Hypertension was the most common
comorbid condition across all the groups (range, 65.1%-71.5%). TEs
had occurred before the index date in 278 of 1876 patients (15.3%;
rate, 69.5/100 patient-years), which were used only for the sensitivity
analyses.
WBC Counts and TEs During Follow-up
The mean follow-up period across the groups ranged from
3.6 to 4.5 years (Table 2). During the follow-up period, thepart during identification period 
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Table 1 Patient Demographics and Baseline Disease Characteristics
Parameter
WBC Count (3109/L)
<7.0 (n [ 428) 7.0-8.4 (n [ 375) 8.5 to <11.0 (n [ 284) ‡11.0 (n [ 478)
Age, y
Mean  standard deviation 64.7  10.8 63.7  10.1 65.3  10.4 67.7  10.8
Median 64.0 63.0 64.0 67.0
Age group
18-45 y 9 (2.1) 11 (2.9) 5 (1.8) 6 (1.3)
46-59 y 142 (33.2) 131 (34.9) 93 (32.8) 123 (25.7)
60 y 277 (64.7) 233 (62.1) 186 (65.5) 349 (73.0)
Sex
Male 424 (99.1) 370 (98.7) 280 (98.6) 467 (97.7)
Female 4 (0.9) 5 (1.3) 4 (1.4) 11 (2.3)
Race
Non-Hispanic white 256 (59.8) 242 (64.5) 193 (68.0) 331 (69.3)
Non-Hispanic black 44 (10.3) 23 (6.1) 15 (5.3) 27 (5.7)
Hispanic 15 (3.5) 17 (4.5) 9 (3.2) 15 (3.1)
Other 113 (26.4) 93 (24.8) 67 (23.6) 105 (22.0)
US region
Northeast 59 (13.8) 49 (13.1) 40 (14.1) 80 (16.7)
Midwest 99 (23.1) 84 (22.4) 65 (22.9) 97 (20.3)
South 158 (36.9) 141 (37.6) 103 (36.3) 177 (37.0)
West 85 (19.9) 84 (22.4) 68 (23.9) 101 (21.1)
Other 27 (6.3) 17 (4.5) 8 (2.8) 23 (4.8)
Charlson comorbidity index score 1.11  1.50 1.28  1.59 1.31  1.48 1.45  1.73
Chronic disease score 6.15  3.95 6.24  4.02 6.66  4.37 6.76  4.13
Comorbid conditions
Dyslipidemia 182 (42.5) 172 (45.9) 125 (44.0) 168 (35.2)
Hypertension 291 (68.0) 244 (65.1) 203 (71.5) 330 (69.0)
Diabetes 86 (20.1) 96 (25.6) 70 (24.7) 126 (26.4)
Cardiovascular events 44 (10.3) 39 (10.4) 40 (14.1) 48 (10.0)
Bleeding 33 (7.7) 29 (7.7) 31 (10.9) 47 (9.8)
Smokinga 101 (23.6) 116 (30.9) 88 (31.0) 119 (24.9)
Data presented as n (%) and mean  standard deviation.
Abbreviation: WBC ¼ white blood cell.
aPercentage determined from the number of patients reporting the use of smoking cessation therapy.
VHA PV WBC and TE Analysis
4 - Clirates of cytoreductive treatment, including phlebotomy, were
similar across the 4 groups. Cytoreductive treatment was
received by 77.3% to 78.2% of patients, including 56.9% to
65.9% who had undergone  1 phlebotomy procedure. Anti-
platelet agents were used by 4.4% to 5.1% of patients across
the 4 groups.
Overall, 390patients (24.9%)experiencedaTEduring the follow-up
period, including 85 (19.9%) with a WBC count < 7.0 109/L, 91
(24.3%) with a WBC count of 7.0 to 8.4109/L, 73 (25.7%) with a
WBC count of 8.5 to< 11.0109/L, and 141 (29.5%) with a WBC
countof11.0109/L (Table3,Figure3).Themeanintervalbetween
the last WBC count and the first TE in these patients was 26.3 days
(median, 0 days; range, 0-758 days), with > 80% of TEs occurring
within 30 days of the lastWBCmeasurement.
Compared with the reference group (WBC count,< 7.0109/L),
the hazard ratio for TEs was 1.10 (95%CI, 0.82-1.48; P¼ .5395) fornical Lymphoma, Myeloma & Leukemia Month 2019the 7.0 to 8.4109/L group, 1.47 (95%CI, 1.10-1.96;P¼ .0097) in
the 8.5 to < 11.0 109/L group, and 1.87 (95% CI, 1.44-2.43;
P < .0001) in the  11.0 109/L group (Table 3), considering the
WBC count as a time-dependent covariate. Similar results were also
observed using a univariate Cox proportional hazards model with the
last WBC count before a TE (in which the WBC counts were not
considered time-dependent). Compared with the reference group
(WBC count,< 7.0109/L), the hazard ratio for TEs was 1.22 (95%
CI, 0.91-1.64; P ¼ .1835), 1.39 (95% CI, 1.02-1.90; P ¼ .0401),
and 1.81 (95% CI, 1.39-2.38; P < .0001) among patients with a
WBC count of 7.0 to 8.4, 8.5 to < 11.0, and  11.0 109/L,
respectively. A similar trend was observed when including all patients
regardless of the occurrence of TEs before the index date (n¼ 1876).
The hazard ratios for TEs compared with the reference group (WBC
count,< 7.0109/L) was 1.22 (95% CI, 0.97-1.55; P¼ .0959) for
the patients in the 7.0 to 8.4 109/L group, 1.41 (95% CI,











Follow-up, y 4.5  1.9 4.5  1.9 4.2  2.0 3.6  2.1
Cytoreductive treatment 331 (77.3) 290 (77.3) 221 (77.8) 374 (78.2)
Phlebotomy 254 (59.4) 233 (62.1) 187 (65.9) 272 (56.9)
Phlebotomies per patient, n 11.3  10.0 11.9  10.9 10.9  10.9 11.1  12.4
Phlebotomies per patient annually, n 2.6  2.3 2.6  2.2 4.7  26.6 3.0  3.3
Hydroxyurea 141 (32.9) 79 (21.1) 71 (25.0) 198 (41.4)
Radiophosphorus 9 (2.1) 11 (2.9) 6 (2.1) 13 (2.7)
Anagrelide 7 (1.6) 10 (2.7) 7 (2.5) 47 (9.8)
Interferon 7 (1.6) 3 (0.8) 7 (2.5) 12 (2.5)
Busulfan 1 (0.2) 1 (0.3) 1 (0.4) 1 (0.2)
Pipobroman 0 (0) 0 (0) 0 (0) 0 (0)
Antiplatelet agents 22 (5.1) 19 (5.1) 14 (4.9) 21 (4.4)
Use of other medications
Antihypertensive agents 386 (90.2) 336 (89.6) 249 (87.7) 445 (93.1)
Antilipid/anticholesterol agents 258 (60.3) 254 (67.7) 173 (60.9) 242 (50.6)
Inotropic agents 27 (6.3) 23 (6.1) 26 (9.2) 43 (9.0)
Antiarrhythmic agents 22 (5.1) 20 (5.3) 16 (5.6) 31 (6.5)
Data presented as mean  standard deviation or n (%).
Abbreviation: WBC ¼ white blood cell.
aBefore the thrombotic event or at the end of follow-up if no thrombotic event had occurred.
Shreekant Parasuraman et al1.10-1.81; P¼ .0062) in the 8.5 to< 11.0109/L group, and 1.53
(95% CI, 1.23-1.91; P ¼ .0001) in the  11.0 109/L group.
Discussion
The results from the present analysis of 1565 patients with PV in the
VHA population have substantiated the findings from a post hoc
subanalysis of the CYTO-PV study in a real-world setting.4 Both
studies have shown that an elevated WBC count is significantly asso-
ciated with an increased risk of TEs. The strongest hazard ratio of 1.87
was observed for the patients with a WBC count of  11 109/L.
However, the thrombotic risk was still observed to be significantly
elevated even in those with a WBC count of 8.5109/L.
Other real-world studies have reported a similar association be-
tween the WBC count and thrombotic risk in patients with PV. In a
multivariate analysis of a retrospective database study of 587 pa-
tients with PV, previous TEs (hazard ratio, 1.9; 95% CI, 1.2-2.9;
P ¼ .03) and WBC count of  11 109/L (hazard ratio, 1.3; 95%
CI, 0.9-2.0; P ¼ .03) were associated with an increased risk ofTable 3 WBC Count and Thrombotic Event Occurrence Rates in US
Covariate
Parameter <7.0 (n [ 428) 7.0-8.4 (n [
Occurrence of TE, n (%) 85 (19.9) 91 (24.3
Hazard ratio (95% CI) Referencea 1.10 (0.82
P value Referencea .5395
Abbreviations: CI ¼ confidence interval; PV ¼ polycythemia vera; TE ¼ thrombotic event; WBC ¼
aWBC count < 7.0 109/L served as the reference group.future TEs.5 In the ECLAP study, a significant risk of major
thrombosis was observed with a WBC count > 15 109/L
compared with a WBC count of  10 109/L (hazard ratio, 1.71;
95% CI, 1.10-2.65; P ¼ .017).3
These findings suggest that control of the WBC count should be
an important consideration in the disease management in PV. The
current National Comprehensive Cancer Network clinical practice
guidelines in oncology for myeloproliferative neoplasms have sug-
gested that cytoreductive treatment should be initiated or changed
in the setting of symptomatic patients with indications for cytore-
ductive therapy, including leukocytosis.1
One fourth (390 of 1565) of the patients in the present study had
experienced a TE during the follow-up period, indicating a sub-
stantial thrombotic burden. A previous analysis of all patients with
PV (n ¼ 7718) in this VHA population revealed a TE rate of 6.1
(arterial, 4.1; venous, 2.1) per 100 patient-years, greater than the
reported rate for high-risk patients with PV in the general popula-
tion.6 Furthermore, the results from the present analysis haveVeterans With PV, Considering WBC Count as a Time-dependent
WBC Count (3109/L)
375) 8.5 to < 11.0 (n [ 284) ‡11.0 (n [ 478)
) 73 (25.7) 141 (29.5)
-1.48) 1.47 (1.10-1.96) 1.87 (1.44-2.43)
.0097 <.0001
white blood cell.
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6 - Clidemonstrated that approximately one third of patients with PV in
the VHA population had elevated WBC levels, compared with
25.5% in the CYTO-PV study,4 which could also have contributed
to increased thrombotic risk.
The limitations of the present study were generally related to the
retrospective study design. The study included patients based on the
ICD-9-CM codes within the medical claims, which have a potential
for miscoding and will not capture potential confounding factors
related to the occurrence of TEs. In the present study, 99% of the
patients were men, which precluded analysis of the association of
the WBC count and TEs in women. Additionally, the clinical data
that could have influenced the thrombotic risk (eg, cytoreductive
therapy, platelet count, hematocrit values) were not used in the
present analysis.
Conclusion
The results from the present analysis of VHA patients with PV
demonstrate a positive, significant association between elevated
WBC counts and the occurrence of TEs and represent real-world
confirmation of the results from the post hoc subanalysis of the
CYTO-PV study. Patients with WBC counts of  8.5 109/L had
a significantly increased risk of TE, and those with WBC counts
of  11.0 109/L had the greatest risk. The potential thrombo-
genic role of elevated WBCs in those with PV provides support for
the continued inclusion of WBC count control in disease man-
agement and the evaluation of the response to therapy.
Clinical Practice Points
 Leukocytosis has been linked to an elevated risk of vascular
events.
 In the present retrospective, observational study of longitudinal
data from the US VHA claims database, the patients werenical Lymphoma, Myeloma & Leukemia Month 2019assigned to groups according to the last WBC count before the
first TE or the end of follow-up (WBC count, <7.0 [reference],
7.0-8.4, 8.5 to < 11.0, and  11.0 109/L).
 Overall, 25% of the 1565 patients experienced a TE during
follow-up, > 80% of which occurred within 30 days of the last
WBC count.
 Compared with the reference group (WBC count,< 7.0109/L),
patients with WBC counts of 8.5 to < 11.0 and  11.0 109/L
had a significantly increased risk of TEs.
 The findings from the present real-world study have confirmed
the potential thrombogenic role of elevated WBCs in those with
PV and provide support for the continued inclusion of WBC
count control in disease management and evaluation of the
therapeutic response.Acknowledgments
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